RecruitingNCT06136949
The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study
The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study: a Monocentric Observational Study
Sponsor
Centro di Riferimento Oncologico - Aviano
Enrollment
150 participants
Start Date
May 22, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims at verifying the overexpression of STARD3 in both early and advanced CRC patients derived tissues, to identify the pathways underpinning tumorigenesis and cancer progression in which STARD3 is involved. Moreover its role as a dynamic biomarker of treatment response and its part in treatment sensitivity will be explored.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Histologically confirmed diagnosis of colorectal cancer, independently from diagnosis stage.
- Age ≥18 years.
- Signed informed consent form.
- Availability of tissue and blood samples stored at the Institutional Biobank for research purposes.
Exclusion Criteria3
- Patients for which the tumour biobanking process could compromise the diagnostic assessments.
- Pregnancy or breast-feeding.
- History of concomitant or previous malignancy in the previous 5 years, except for adequately treated cutaneous squamous cell carcinoma or surgically removed in situ cervical carcinoma.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06136949
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations
Camera Capsule Endoscopy in the Routine Diagnostic Pathway for Colorectal Diseases
NCT064755601 location
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
NCT069922589 locations